Other
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified: > Other: > Other
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Subheadings
Products classified under HTS 3002.90.52
Human Serum Albumin 20% Solution
A sterile solution of human serum albumin at 20% concentration, prepared from human plasma for therapeutic use in treating hypovolemia and shock. It falls under HTS 3002.90.52 as a blood fraction prepared for therapeutic uses. This product is biotechnologically processed to ensure purity and safety.
Anti-Hemophilic Factor VIII Concentrate
A lyophilized concentrate of coagulation Factor VIII derived from human plasma, used therapeutically for hemophilia A treatment. Classified under HTS 3002.90.52 as an other blood fraction prepared for therapeutic uses via biotechnological purification. It replaces missing clotting factors in patients.
IVIG Intravenous Immunoglobulin
A pooled immunoglobulin G preparation from human plasma for intravenous administration in immunodeficiency disorders. HTS 3002.90.52 covers it as other blood fractions prepared for therapeutic uses. Biotechnological processes ensure high purity and immune modulation.
Cryoprecipitated Antihemophilic Factor
Cryoprecipitate from fresh frozen plasma containing Factor VIII, fibrinogen, and von Willebrand factor for therapeutic clotting support. Under HTS 3002.90.52 as other animal/human blood products prepared for therapeutic uses. Commonly used in surgical bleeding management.
Monoclonal Antibody Infusion for Cancer Therapy
Biotechnologically produced monoclonal antibodies like rituximab for therapeutic infusion in lymphoma treatment. HTS 3002.90.52 includes such immunological products prepared for therapeutic uses. They target specific cancer cells via immune regulation.
Botulism Antitoxin Serum
Equine-derived antiserum containing antibodies against botulinum toxin for therapeutic treatment of botulism poisoning. Classified in HTS 3002.90.52 as other antisera prepared for therapeutic uses. Essential for emergency prophylactic administration.
Rh Immune Globulin Injection
Human anti-D immunoglobulin for prophylactic prevention of Rh hemolytic disease in newborns. HTS 3002.90.52 as other blood fractions and immunological products for prophylactic uses. Administered to Rh-negative mothers post-delivery.
Interferon Beta-1a for Multiple Sclerosis
Recombinant human interferon beta-1a injection for therapeutic management of relapsing multiple sclerosis. Under HTS 3002.90.52 as an immunological product involved in immune regulation. Biotechnologically produced for weekly subcutaneous use.
Cytomegalovirus Immune Globulin
Hyperimmune globulin from donors with high CMV antibody titers for prophylactic use in transplant patients. HTS 3002.90.52 covers other immunological products prepared for prophylactic uses. Prevents CMV infection in immunocompromised individuals.
Tumor Necrosis Factor Inhibitor Injection
Biotech TNF-alpha inhibitor like infliximab for therapeutic treatment of rheumatoid arthritis and Crohn's disease. Classified under HTS 3002.90.52 as modified immunological products regulating immune processes. Administered via infusion for chronic inflammation.